Answers are grounded in this paper and cite their sources.
Retrospective analysis shows trastuzumab deruxtecan improves outcomes in HER2-mutant NSCLC, highlighting optimal therapies.
e20502 Background: The HER2-targeted therapy trastuzumab deruxtecan (T-DXd) was approved for use in China in 2024, providing a novel option for patients with HER2-mutant non-small cell lung cancer (NSCLC). Despite its approval, data on treatment patterns and clinical outcomes in real-world settings remain scarce. This study aimed to analyze real-world treatment patterns and outcomes in HER2-mutant NSCLC, providing a foundation for optimizing HER2-targeted therapies in clinical practice. Methods: This retrospective analysis included clinical data from HER2-mutant NSCLC patients treated across four medical centers (Peking University Cancer Hospital & Institute, Peking University Cancer Hospital (Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University, The second affiliated hospital of Dalian medical university and The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital) between December 2015 and April 30, 2025. Statistical analyses were performed using SPSS software and included log-rank tests, Kaplan-Meier survival analyses, univariate and multivariate models, and Clopper-Pearson interval estimation. Results: 404 patients with HER2-altered NSCLC were included, of whom 49.75% (201/404) had HER2 exon 20 insertion mutations. Among patients harboring HER2 mutations (with or without amplification) receiving first-line therapy, trastuzumab deruxtecan (T-DXd) monotherapy achieved a median real-world progression-free survival (rwPFS) of 19.40 months (N = 11), which was significantly longer than chemotherapy (N = 34, 5.90 months), immunotherapy-based regimens (N = 106, 8.20 months), non-T-DXd HER2-targeted therapy (N = 25, 6.07 months), and anti-angiogenic based therapy (N = 44, 8.47 months) (P = 0.04). For second-line therapy, the median rwPFS of T-DXd monotherapy (N = 25, 10.13 months) was numerically longer than chemotherapy (N = 11, 3.90 months) and IO-based therapy (N = 28, 6.03 months) (P = 0.25). Conclusions: This is the largest real-world cohort study of HER2-mutant NSCLC to date. Real-world treatment strategies for HER2-mutant NSCLC patients are highly variable. T-DXd demonstrated the most favorable outcomes in both the first-line and second-line settings, showing superior effectiveness compared to other available treatments. These findings underscore the potential of T-DXd as a key therapeutic option for HER2-mutant NSCLC patients. Future studies are warranted to further validate these real-world outcomes and explore optimal therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: